NMDA receptor antagonists play a crucial role in Alzheimer's disease and dementia by modulating glutamate activity in the brain. Glutamate, an excitatory neurotransmitter, is implicated in neurodegenerative processes when present in excess. NMDA receptor antagonists, such as memantine, work by blocking these receptors, thereby regulating glutamate levels and reducing neuronal damage associated with Alzheimer's disease progression. This class of drugs helps improve cognitive function and delay symptom progression by maintaining neurotransmitter balance. Unlike other treatments, NMDA receptor antagonists target specific mechanisms of neurodegeneration, offering a unique therapeutic approach in managing Alzheimer's disease and related dementias. Ongoing research continues to explore their efficacy and potential in providing symptomatic relief and possibly altering disease progression in affected individuals.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China